Bio-Rad Laboratories, Inc.

NYSE BIO

Bio-Rad Laboratories, Inc. Free Cash Flow Per Share for the Trailing 12 Months (TTM) ending September 30, 2024: USD 7.85

Bio-Rad Laboratories, Inc. Free Cash Flow Per Share is USD 7.85 for the Trailing 12 Months (TTM) ending September 30, 2024, a 3.68% change year over year. Free cash flow per share is the free cash flow generated per share. Indicates investment potential based on cash flow generation.
  • Bio-Rad Laboratories, Inc. Free Cash Flow Per Share for the Trailing 12 Months (TTM) ending September 30, 2023 was USD 7.57, a 49.20% change year over year.
  • Bio-Rad Laboratories, Inc. Free Cash Flow Per Share for the Trailing 12 Months (TTM) ending September 30, 2022 was USD 5.08, a -77.30% change year over year.
  • Bio-Rad Laboratories, Inc. Free Cash Flow Per Share for the Trailing 12 Months (TTM) ending September 30, 2021 was USD 22.36, a 80.54% change year over year.
  • Bio-Rad Laboratories, Inc. Free Cash Flow Per Share for the Trailing 12 Months (TTM) ending September 30, 2020 was USD 12.39, a 35.69% change year over year.
Key data
Date Free Cash Flow Per Share Return on Assets (ROA) Return on Equity (ROE) Return on Capital Employed (ROCE)
Market news
Loading...
NYSE: BIO

Bio-Rad Laboratories, Inc.

CEO Mr. Norman D. Schwartz
IPO Date Feb. 27, 1980
Location United States
Headquarters 1000 Alfred Nobel Drive
Employees 7,700
Sector Health Care
Industries
Description

Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. In addition, the company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

Similar companies

PODD

Insulet Corporation

USD 267.04

-0.35%

BRKR

Bruker Corporation

USD 61.26

-2.69%

INSP

Inspire Medical Systems, Inc.

USD 169.99

-3.10%

CNMD

CONMED Corporation

USD 67.79

-2.46%

GMED

Globus Medical, Inc.

USD 88.18

1.15%

DXCM

DexCom, Inc.

USD 79.17

-0.84%

STE

STERIS plc

USD 207.57

0.10%

ITGR

Integer Holdings Corporation

USD 138.83

2.72%

ZBH

Zimmer Biomet Holdings, Inc.

USD 104.71

-0.74%

NARI

Inari Medical, Inc.

USD 79.30

-0.05%

TNDM

Tandem Diabetes Care, Inc.

USD 35.79

-1.16%

PEN

Penumbra, Inc.

USD 252.89

2.41%

NVCR

NovoCure Limited

USD 26.23

-4.20%

ANIK

Anika Therapeutics, Inc.

USD 15.58

-2.14%

GKOS

Glaukos Corporation

USD 147.95

-2.58%

StockViz Staff

January 15, 2025

Any question? Send us an email